{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:49:51Z","timestamp":1788990591532,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01971-x","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:54:55Z","timestamp":1767776095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of eltrombopag in combination with cyclosporine A for the treatment of adult refractory primary immune thrombocytopenia: a phase II, multicenter, single-arm, prospective study"],"prefix":"10.1007","volume":"26","author":[{"given":"Changle","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"6","key":"1971_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","volume":"16","author":"S Audia","year":"2017","unstructured":"Audia S, Mah\u00e9vas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620\u201332.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1971_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.26036","volume":"96","author":"N Cooper","year":"2021","unstructured":"Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199\u2013207.","journal-title":"Am J Hematol"},{"issue":"5","key":"1971_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","volume":"101","author":"N Vianelli","year":"2022","unstructured":"Vianelli N, Auteri G, Buccisano F, et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. 2022;101(5):963\u201378.","journal-title":"Ann Hematol"},{"issue":"7","key":"1971_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.2019003599","volume":"135","author":"O Miltiadous","year":"2020","unstructured":"Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472\u201390.","journal-title":"Blood"},{"issue":"23","key":"1971_CR5","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"issue":"6","key":"1971_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.24702","volume":"92","author":"G Moulis","year":"2017","unstructured":"Moulis G, Germain J, Comont T, et al. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493\u2013500.","journal-title":"Am J Hematol"},{"issue":"2","key":"1971_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","volume":"32","author":"S Birocchi","year":"2021","unstructured":"Birocchi S, Podda GM, Manzoni M, Casazza G, Cattaneo M. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216\u201326.","journal-title":"Platelets"},{"issue":"22","key":"1971_CR8","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780\u2013817.","journal-title":"Blood Adv"},{"key":"1971_CR9","doi-asserted-by":"crossref","unstructured":"Provan D. and J. W. Semple. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022; 76(103820.","DOI":"10.1016\/j.ebiom.2022.103820"},{"issue":"21","key":"1971_CR10","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.3760\/cma.j.issn.0366-6999.20131116","volume":"126","author":"ZG Cui","year":"2013","unstructured":"Cui ZG, Liu XG, Qin P, et al. Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia. Chin Med J. 2013;126(21):4145\u20138.","journal-title":"Chin Med J"},{"issue":"9","key":"1971_CR11","first-page":"996","volume":"43","author":"L Cao","year":"2021","unstructured":"Cao L, Pan Q, Fan C, et al. The effect of Eltrombopag combined with cyclosporine A in the treatment of immune thrombocytopenia: an observational study. Zhejiang Med J. 2021;43(9):996\u20131002.","journal-title":"Zhejiang Med J"},{"issue":"8","key":"1971_CR12","first-page":"617","volume":"41","author":"M Hou","year":"2020","unstructured":"Hou M, Hu Y. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020). Chin J Hematol. 2020;41(8):617\u201323.","journal-title":"Chin J Hematol"},{"issue":"11","key":"1971_CR13","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"key":"1971_CR14","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD: National Cancer Institute. 2017."},{"issue":"7","key":"1971_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/aps.2015.6","volume":"36","author":"YX Wang","year":"2015","unstructured":"Wang YX, Li JL, Wang XD, et al. Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. Acta Pharmacol Sin. 2015;36(7):855\u201362.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1971_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.14380","volume":"176","author":"R Yang","year":"2017","unstructured":"Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of Eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101\u201310.","journal-title":"Br J Haematol"},{"issue":"6","key":"1971_CR17","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/ije\/dyac123","volume":"51","author":"Y Ouyang","year":"2022","unstructured":"Ouyang Y, Li F, Preisser JS, Taljaard M. Sample size calculators for planning stepped-wedge cluster randomized trials: a review and comparison. Int J Epidemiol. 2022;51(6):2000\u201313.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"1971_CR18","first-page":"942","volume":"39","author":"YT Huang","year":"2018","unstructured":"Huang YT, Liu XF, Chen YF, et al. [The incidence and risk factors for thrombosis in primary immune thrombocytopenia]. Zhonghua Xue Ye Xue Za zhi = Zhonghua Xueyexue Zazhi. 2018;39(11):942\u20136.","journal-title":"Zhonghua Xue Ye Xue Za zhi = Zhonghua Xueyexue Zazhi"},{"key":"1971_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221097780","volume":"13","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Cantoni S, Giannotta JA. Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers. Ther Adv Hematol. 2022;13:20406207221097780.","journal-title":"Ther Adv Hematol"},{"key":"1971_CR20","doi-asserted-by":"crossref","unstructured":"Wang T, He X, Ran N et al. Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. J Clin Lab Anal. 2021;35(9):e23922.","DOI":"10.1002\/jcla.23922"},{"issue":"5","key":"1971_CR21","doi-asserted-by":"publisher","first-page":"100279","DOI":"10.1016\/j.rpth.2023.100279","volume":"7","author":"Y Hong","year":"2023","unstructured":"Hong Y, Shen Y, Liu Q, et al. Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study. Res Pract Thromb Haemostasis. 2023;7(5):100279.","journal-title":"Res Pract Thromb Haemostasis"},{"key":"1971_CR22","doi-asserted-by":"crossref","unstructured":"Kahan BD. Cyclosporine. N Engl J Med. 1989;321(25):1725-38.","DOI":"10.1056\/NEJM198912213212507"},{"issue":"3","key":"1971_CR23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1365-2141.2002.03709.x","volume":"118","author":"AS Levy","year":"2002","unstructured":"Levy AS, Cunningham-Rundles S, Mazza B, et al. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;118(3):836\u20138.","journal-title":"Br J Haematol"},{"key":"1971_CR24","doi-asserted-by":"crossref","unstructured":"Sikic BI, Fisher GA, Lum BL et al. Modulation\tand\tprevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40(suppl 1):S13\u2013S19.","DOI":"10.1007\/s002800051055"},{"issue":"3","key":"1971_CR25","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.3324\/haematol.2019.226688","volume":"105","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhang BM, Guo X, et al. Blood transcriptome and clonal T-cell correlates of response and non-response to Eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Haematologica. 2020;105(3):e129\u201332.","journal-title":"Haematologica"},{"issue":"3","key":"1971_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2249.2003.02239.x","volume":"133","author":"PF Fogarty","year":"2003","unstructured":"Fogarty PF, Rick ME, Zeng W, et al. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol. 2003;133(3):461\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"1971_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/nm921","volume":"9","author":"B Olsson","year":"2003","unstructured":"Olsson B, Andersson PO, Jern\u00e5s M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123\u20134.","journal-title":"Nat Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01971-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:02:25Z","timestamp":1768928545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01971-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01971-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, The First Affiliated Hospital Affiliated to Zhejiang University School of Medicine, and Tongde Hospital of Zhejiang Province institutional review boards in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"104"}}